Sharon Hesterlee's Blog – January 2013 Archive (1)
Sarepta Summary of Outstanding Questions from PPMD Webinar
On October 23, 2012, PPMD hosted a webinar with Sarepta to discuss of the 48 Week dystrophin and 6-minute walk test (6MWT) data from the Phase IIb extension study in Duchenne as well as next steps for the eteplirsen program. Chris Garabedian, President and CEO of Sarepta…
Added by Sharon Hesterlee on January 17, 2013 at 12:00pm — No Comments
Latest Blog Posts
Most Popular Blog Posts
- GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen
- Positive Phase 1 trial results for SMT C1100 in Duchenne (Summit PLC)
- Now is the time for strength.
- Without Endings There Are No Beginnings…
- Parent Project Muscular Dystrophy awards $50,000 to Dr. Toshifumi Yokota for multi-exon skipping project
- Drug Development Prospects for Duchenne: The Pipeline is rich and deep, with lots of forward momentum
- World Muscle Society Congress: Next Generation Exon-Skipping & Clinical Trial Updates
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
